Clinical trials: Glycemic Control for Diabetes Mellitus
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
Type 1 Diabetes Mellitus
VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14299 and VV-14300 or VV-14300 alone in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- PROGRESS (NCT07829302)
- Testing
- VV-14300, VV-14299
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.
- Trial name
- COMMIT (NCT00676741)
- Testing
- insulin aspart, biphasic insulin aspart 30, insulin detemir
- Where
- Slovakia
- Volunteers
- 3,809 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units
The primary purpose of this study is to demonstrate that the BD 4mm x 32G Ultra-Fine Nano pen needle provides equivalent glycemic control to the BD 8mm x 31G Ultra-Fine short pen needle as measured by fructosamine (FRU) among…
- Trial name
- NCT01334606
- Testing
- 4 mm x 32G pen needle (Nano), 8mm x 31G pen needle (Short)
- Where
- 3 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 2
Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance
This randomized, double-blind placebo-controlled study is intended to observe the short-term effects of the GFL System Diet with Release supplement versus GFL System Diet with placebo on glycemic metabolism and insulin resistance…
- Trial name
- NCT04082390
- Testing
- RELEASE
- Volunteers
- 36 people
- Sponsor
- Golo
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Type 2 Diabetes, Obese
The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2…
- Conditions
- Type 2 Diabetes, Obese, Overweight, Prediabetes
- Trial name
- NCT05844644
- Testing
- Release
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Golo
Diabetes Mellitus
Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin
To demonstrate the superiority of a chronic care model (SINERGIA model) supported by the Self Monitoring of Blood Glucose with BGStar over usual care in improving glycemic control at 12 months in patients with type 2 diabetes not…
- Trial name
- SELF CARE (NCT02082028)
- Testing
- BGStar, glucose meter
- Where
- 20 sites in Italy
- Volunteers
- 241 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control
This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood…
- Trial name
- LIGHT (NCT00700960)
- Testing
- insulin detemir
- Where
- France
- Volunteers
- 2,745 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy.
- Trial name
- NCT01678820
- Testing
- Sitagliptin/Simvastatin FDC, Sitagliptin, Simvastatin
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.
The purpose of the study is to evaluate the efficacy in glycemic control and the impact on the quality of life of patients using the MiniMed™ 780G System for the treatment of Type 1 diabetes, in real life settings in France.
- Trial name
- NCT04308291
- Testing
- MiniMed™ 780G System
- Where
- 32 sites in France
- Volunteers
- 306 people
- Sponsor
- Medtronic MiniMed, Inc.
Typ 2 Diabetes, Obesity
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
Approval study Trans-Duodenal Barrier The goal of this clinical trial is to determin the safety and performance of the newly developed Trans-Duodenal Barrier in adult Tryp 2 diabetic and obese patients.
- Conditions
- Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
- Trial name
- LuST (NCT07417683)
- Testing
- endoscopic implant
- Where
- 8 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Trans-Duodenal Concepts GmbH
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
This 4 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin.
- Trial name
- NCT00754988
- Testing
- Metformin, Sitagliptin, Taspoglutide
- Where
- 148 sites in United States, Argentina and 21 more
- Volunteers
- 666 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
- Trial name
- NCT00046462
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2 Diabetes
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT01485614
- Testing
- Sitagliptin, Metformin, Glycemic Rescue 1
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
PreDiabetes, Diabetes Mellitus, Type 2
Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-Care
The purpose of this research is to understand the impact of medically tailored meals on health-related biometrics (e.g., glucose time-in-range, waist-hip ratio, cholesterol) and how providing medically tailored meals promotes…
- Trial name
- NCT04810026
- Testing
- Education, Meal delivery, Lifestyle coaching
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- UnitedHealth Group
Diabetes Type 2
A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus
Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.
- Trial name
- ACTION-DM (NCT05302050)
- Testing
- BT-001, Control Mobile Application
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Better Therapeutics
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Non-Insulin-Dependent
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00837577
- Testing
- Sitagliptin, Voglibose
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections
The purpose of this study is to evaluate that Finesse, for prandial insulin bolusing when used in conjunction with basal insulin, achieves equivalent glycemic control when compared to multiple daily injections and to evaluate its…
- Trial name
- NCT01073566
- Testing
- Finesse, Pen/Syringe (Usual injection device)
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Calibra Medical, Inc.